Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 90

Results For "ANDA"

2103 News Found

NTPC partners with Apollo Hospitals to introduce Tele-Emergency and Tele-ICU Services across its 9 plants locations
News | September 07, 2023

NTPC partners with Apollo Hospitals to introduce Tele-Emergency and Tele-ICU Services across its 9 plants locations

These plant locations include Ramagundam, Talcher Kaniha, Korba, Vindhyachal, Dadri, Barh, Solapur, North Karanpura, and Mauda


Aptar appoints Sarah Glickman to its Board of Directors
People | September 07, 2023

Aptar appoints Sarah Glickman to its Board of Directors

Sarah currently serves as the Chief Financial Officer and Principal Accounting Officer for Criteo S.A.


Amgen olpasiran may fill critical treatment gap in lowering Lp(a): GlobalData
News | September 06, 2023

Amgen olpasiran may fill critical treatment gap in lowering Lp(a): GlobalData

This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)


Caplin Steriles receives EIR from US FDA
Drug Approval | September 05, 2023

Caplin Steriles receives EIR from US FDA

The inspection classification was determined by the agency as Voluntary Action Indicated


Zydus receives final USFDA approval for Erythromycin Tablets
Drug Approval | September 03, 2023

Zydus receives final USFDA approval for Erythromycin Tablets

Erythromycin tablets is used to prevent and treat infections in many different parts of the body


Shilpa Pharma Lifesciences’ Unit II, Raichur, Karnataka clears PMDA Japan, GMP inspection
Drug Approval | September 02, 2023

Shilpa Pharma Lifesciences’ Unit II, Raichur, Karnataka clears PMDA Japan, GMP inspection

The inspection has concluded successfully on 1st September 2023 without any critical/major observation


USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes
Drug Approval | September 01, 2023

USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes

Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia


Strides receives USFDA approval for Mycophenolate Mofetil for oral suspension
Drug Approval | August 31, 2023

Strides receives USFDA approval for Mycophenolate Mofetil for oral suspension

The approval bolsters the company's Mycophenolate Mofetil portfolio